Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market: Imatinib ACTe 100mg and Nilotinib ACTe 200mg.

Imatinib ACTe 100mg is the generic version of Gleevec, a chemotherapy medication used to treat chronic myelogenous leukemia and acute lymphocytic leukemia that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors, hypereosinophilic syndrome, chronic eosinophilic leukemia, systemic mastocytosis, and myelodysplastic syndrome. Nilotinib ACTe 200mg is the generic version of Tasigna, used for the treatment of imatinib-resistant chronic myelogenous leukemia.

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.